Investor Relations

Overview

BioXcel Therapeutics, Inc. (Nasdaq: BTAI) is a biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology. The Company’s drug re-innovation approach leverages existing approved drugs and/or clinically validated product candidates together with big data and proprietary machine learning algorithms to identify new therapeutic indications. 
 
The Company’s commercial product, IGALMI™ (developed as BXCL501), is a proprietary, sublingual film formulation of dexmedetomidine approved for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults. The safety and effectiveness of IGALMI has not been established beyond 24 hours from the first dose. For more information, please visit IGALMIhcp.com and also see the IGALMI full Prescribing Information.
 
BXCL501 is under evaluation for at-home use for the acute treatment of agitation in patients with schizophrenia or bipolar disorders, for the acute treatment of agitation associated with Alzheimer’s disease, and as an adjunctive treatment for major depressive disorder. The safety and efficacy of BXCL501 for these uses have not been established. The Company is also developing BXCL502 as a potential therapy for chronic agitation in dementia. 
 
Under its subsidiary, OnkosXcel Therapeutics, the Company is developing BXCL701, an investigational, oral systemic innate immune activator for the treatment of aggressive forms of prostate cancer and other solid and liquid tumors. The safety and efficacy of BXCL502 and BXCL701 have not been established.

 

Events

Latest Annual Filing

      Sign Up for Email Alerts
Receive updates straight into your inbox

BioXcel Therapeutics, Inc.


Data Provided by Refinitiv.

Price
Change
Volume
52 Week High
52 Week Low

Contacts

Corporate

BioXcel Therapeutics
Erik Kopp

Investor Relations

BioXcel Therapeutics
Brennan Doyle

Media